Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers

Babar Bashir; John C Flickinger; Adam E Snook

doi:10.2217/imt-2021-0012

Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers

Immunotherapy. 2021 May;13(7):561-564. doi: 10.2217/imt-2021-0012. Epub 2021 Mar 16.

Authors

Babar Bashir^{1

2}, John C Flickinger², Adam E Snook²

Affiliations

¹ Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
² Departments of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA.

PMID: 33724866
DOI: 10.2217/imt-2021-0012

Abstract

Tweetable abstract US FDA-approved immune checkpoint inhibitors have limited efficacy for gastrointestinal cancers such as #colorectalcancer and #pancreaticcancer. Could combinations with experimental cancer 'vaccines' be the key?

Keywords: cancer vaccines; gastrointestinal cancer; immune checkpoint inhibitors; immuno-oncology; microsatellite instability; neoantigens; tumor mutational burden.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Cancer Vaccines / therapeutic use*
Gastrointestinal Neoplasms / drug therapy*
Gastrointestinal Neoplasms / immunology*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Immunotherapy / methods*

Substances

Cancer Vaccines
Immune Checkpoint Inhibitors